9969 Share Price Performance
HK$0
-6.69 (-100.00%)
Price HK$0
Fair ValueHK$25.79
Share Pricen/a
InnoCare Pharma Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
9969 Community Narratives
AN
Fair Value HK$25.79 44.3% undervalued intrinsic discount
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value HK$8.2 75.2% overvalued intrinsic discount
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value HK$18.33 21.7% undervalued intrinsic discount
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
Key Takeaways Strong progress in drug commercialization and pipeline development suggests significant potential for future revenue growth and enhanced earnings. Strategic global expansion and innovative therapies aim to improve net margins and drive long-term revenue stability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
HK$18.33
21.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
30.46% p.a.
Profit Margin
3.95%
Future PE
367.22x
Price in 2028
HK$22.57
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
Key Takeaways Leadership in BTK inhibition and innovative drug pipeline positions the company for rapid, diversified revenue growth and major breakthroughs in multiple therapeutic areas. Strategic expansion into ADCs and strong operational efficiency create high-margin global opportunities, supporting long-term market dominance and sustained margin expansion.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
HK$25.79
44.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
39.24% p.a.
Profit Margin
18.61%
Future PE
61.54x
Price in 2028
HK$45.8
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
Key Takeaways Heavy dependence on a single drug and regulatory risks threaten profitability and revenue stability, especially if late-stage trials or approvals face setbacks. Heightened cost pressures, geopolitical barriers, and aggressive R&D outlays could limit global expansion, compress margins, and suppress future earnings per share.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
HK$8.2
75.2% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
26.36% p.a.
Profit Margin
18.04%
Future PE
27.02x
Price in 2028
HK$14.55
Trending Discussion
Recently Updated Narratives
AN
9969: Expanding Access And Ongoing Trials Will Drive Margin Improvement Ahead
Fair Value: HK$18.33 21.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
Fair Value: HK$8.2 75.2% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
Fair Value: HK$25.79 44.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
InnoCare Pharma Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.14
- 88.40%
- -16.09%
- 24.7%
About 9969
- Founded
- 2015
- Employees
- 1176
- CEO
- WebsiteView website
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a registrational trial for the treatment of solid tumor patients, including cholangiocarcinoma; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase II clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
